Yutrepia, prescribed to over 900 PAH or PH-ILD patients since its May U.S. approval, increased walking distances by over 100 ...

Columnist Jolie Lizana is not just happy to take a day of rest for National Relaxation Day; she contends that such rest is ...

Immune cell metabolism changes may underlie PAH inflammation, which could inform targets for new PAH treatment strategies.

A 5-year-old boy with a neuroblastoma developed PAH after receiving a high dose of chemotherapy to prepare for a stem cell ...

After positive trial results for TX45, Tectonic Therapeutic is planning a Phase 2 study to test its effects on blood flow in ...

People with portopulmonary hypertension (PoPH) show lower survival rates than other PAH types, but targeted PAH treatments ...

To reduce fatigue, the first thing columnist Jen Cueva did was analyze her sleep patterns, revealing some surprising results.

After positive trial results for TX45, Tectonic Therapeutic is planning a Phase 2 study to test its effects on blood flow in PH-ILD patients.

Pulmonary hypertension (PH) is a rare, serious disease characterized by high blood pressure and damaged pulmonary arteries. These vessels, which are responsible for carrying the blood from the right ...

A heart ultrasound measure called tricuspid regurgitation could show risk, especially in those considered low risk, based on other measures.